ATE333868T1 - Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas - Google Patents

Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas

Info

Publication number
ATE333868T1
ATE333868T1 AT01992569T AT01992569T ATE333868T1 AT E333868 T1 ATE333868 T1 AT E333868T1 AT 01992569 T AT01992569 T AT 01992569T AT 01992569 T AT01992569 T AT 01992569T AT E333868 T1 ATE333868 T1 AT E333868T1
Authority
AT
Austria
Prior art keywords
obesity
pyridoxamine
suppression
treatment
product formation
Prior art date
Application number
AT01992569T
Other languages
English (en)
Inventor
John Baynes
Original Assignee
Univ South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Carolina filed Critical Univ South Carolina
Application granted granted Critical
Publication of ATE333868T1 publication Critical patent/ATE333868T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)
AT01992569T 2000-11-02 2001-11-02 Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas ATE333868T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24563000P 2000-11-02 2000-11-02
US31578901P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
ATE333868T1 true ATE333868T1 (de) 2006-08-15

Family

ID=26937355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992569T ATE333868T1 (de) 2000-11-02 2001-11-02 Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas

Country Status (6)

Country Link
US (1) US20020128295A1 (de)
EP (1) EP1341532B1 (de)
AT (1) ATE333868T1 (de)
AU (1) AU2002218002A1 (de)
DE (1) DE60121794D1 (de)
WO (1) WO2002036109A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
DK1643999T3 (da) * 2003-06-20 2012-01-02 Nephrogenex Inc Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
US7214799B2 (en) * 2004-02-09 2007-05-08 Biostratum, Inc. Methods for the synthesis of pyridoxamine
CN100558359C (zh) * 2004-09-06 2009-11-11 兴和株式会社 肾小球病治疗剂
DE102004050353A1 (de) * 2004-10-15 2006-04-20 Basf Ag Verwendung stabiler Ammoniumsalze der Liponsäure zur Behandlung diabetischer und weiterer Störungen
CA2844150C (en) 2011-07-12 2019-09-03 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
BR112019022523A2 (pt) 2017-04-27 2020-05-12 Vanderbilt University Métodos para tratamento de aterosclerose com sequestrantes de gama-cetoaldeído

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
ES2197689T3 (es) * 1998-10-22 2004-01-01 University Of South Carolina Procedimientos para inhibir complicaciones diabeticas.

Also Published As

Publication number Publication date
WO2002036109A3 (en) 2003-05-30
US20020128295A1 (en) 2002-09-12
EP1341532A2 (de) 2003-09-10
EP1341532B1 (de) 2006-07-26
DE60121794D1 (de) 2006-09-07
AU2002218002A1 (en) 2002-05-15
WO2002036109A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
TW200512016A (en) Drug-coated stents and methods of use therefor
DE60042172D1 (de) Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE333868T1 (de) Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE177421T1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE400301T1 (de) Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
NZ304291A (en) Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof
DE69634404D1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
BG101875A (en) New cryptoficins and method for their preparation
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
HK1044467A1 (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE273708T1 (de) Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE378068T1 (de) Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
ATE366579T1 (de) Verfahren zur behandlung von leberkrebs durch intrahepatische verabreichung von nemorubicin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties